Literature DB >> 943193

Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

A M Johnson, D M Loew, J M Vigouret.   

Abstract

1. The activity of bromocriptine has been investigated in tests for the stimulation of central dopaminergic mechanisms. The results obtained have been compared with those of apomorphine, (+)-amphetamine and L-DOPA. 2. Bromocriptine (2.5 to 10 mg/kg) induced stereotyped sniffing and licking in rats. The stereotypy was more intense than that induced by L-DOPA and less intense than that of apomorphine and (+)-amphetamine over the dose ranges studied. 3. In rats lesioned unilaterally in the substantia nigra by local injection of 6-hydroxydopamine, bromocriptine, like apomorphine and L-DOPA, induced turning contralateral to the side of the lesion. The smallest dose of bromocriptine to induce turning was 0.5 mg/kg. 4. Reserpine-induced catalepsy in mice was antagonized by bromocriptine, with an ED50 of 1.8 mg/kg. It was intermediate in potency to apomorphine and L-DOPA. 5. Spontaneous locomotor activity in mice was stimulated by bromocriptine in a dose-dependent manner from 2.5 to 10 mg/kg after an initial suppression of activity. 6. In all experiments, bromocriptine was characterized by a prolonged duration of activity after a delay in the onset of effect. 7. The stereotyped behaviour induced by bromocriptine was inhibited by prior administration of pimozide, reserpine or alpha-methyl-p-tyrosine. 8. Bromocriptine-induced turning behaviour was abolished by pretreatment with pimozide, and reduced after alpha-methyl-p-tyrosine treatment. 9. The results obtained support the conclusion that bromocriptine acts by stimulating dopamine receptors in the central nervous system and that intact catecholamine synthesis and granular amine storage mechanisms are necessary for it to bring about its effects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 943193      PMCID: PMC1666767          DOI: 10.1111/j.1476-5381.1976.tb06959.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  EFFECTS OF ALPHA-METHYL DOPA AND DOPA ON THE AMPHETAMINE EXCITATORY RESPONSE IN RESERPINIZED RATS.

Authors:  R M QUINTON; G HALLIWELL
Journal:  Nature       Date:  1963-10-12       Impact factor: 49.962

2.  ENHANCEMENT BY RESERPINE AND ALPHA-METHYL DOPA OF THE EFFECTS OF D-AMPHETAMINE UPON THE LOCOMOTOR ACTIVITY OF MICE.

Authors:  C B SMITH
Journal:  J Pharmacol Exp Ther       Date:  1963-12       Impact factor: 4.030

3.  BLOCKADE OF ENDOGENOUS NOREPINEPHRINE SYNTHESIS BY ALPHA-METHYL-TYROSINE, AN INHIBITOR OF TYROSINE HYDROXYLASE.

Authors:  S SPECTOR; A SJOERDSMA; S UDENFRIEND
Journal:  J Pharmacol Exp Ther       Date:  1965-01       Impact factor: 4.030

4.  MECHANISM OF ACTION OF PSYCHOMOTOR STIMULANT DRUGS. SIGNIFICANCE OF DOPAMINE IN LOCOMOTOR STIMULANT ACTION.

Authors:  A T HURKMANS
Journal:  Int J Neuropharmacol       Date:  1964-05

5.  [Bulbocapnine catatonia, its synergists and antagonists].

Authors:  G ZETLER; E MOOG
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1958

6.  Enhanced stimulant effects of d-amphetamine in rats treated chronically with reserpine.

Authors:  J M Stolk; R H Rech
Journal:  J Pharmacol Exp Ther       Date:  1968-09       Impact factor: 4.030

7.  Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats.

Authors:  A M Ernst
Journal:  Psychopharmacologia       Date:  1967

8.  Evidence that the central action of amphetamine is mediated via catecholamines.

Authors:  L C Hanson
Journal:  Psychopharmacologia       Date:  1966

9.  On the role of norepinephrine biosynthesis in the central action of amphetamine.

Authors:  J V Dingell; M L Owens; M R Norvich; F Sulser
Journal:  Life Sci       Date:  1967-06-01       Impact factor: 5.037

10.  Histochemical studies on the effect of (positive)-amphetamine, drugs of the imipramine group and tryptamine on central catecholamine and 5-hydroxytryptamine neurons after intraventricular injection of catecholamines and 5-hydroxytryptamine.

Authors:  K Fuxe; U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1968-09       Impact factor: 4.432

View more
  42 in total

1.  Bromocriptine induces marked locomotor stimulation in dopamine-depleted mice when D-1 dopamine receptors are stimulated with SKF38393.

Authors:  D M Jackson; M Hashizume
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice.

Authors:  Olajide S Annafi; Oritoke M Aluko; Anthony T Eduviere; Osarume Omorogbe; Solomon Umukoro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-13       Impact factor: 3.000

3.  Hypothermic action of lisuride in rats and differences to bromocriptine in the antagonistic effect of neuroleptics.

Authors:  R Horowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-03       Impact factor: 3.000

Review 4.  Hypothesis: bromocriptine lacks intrinsic dopamine receptor stimulating properties.

Authors:  D M Jackson; O F Jenkins
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

Review 5.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

6.  Effect of bromocriptine administration on gastric acid and gastrin secretion in man.

Authors:  R Caldara; C Ferrari; M Romussi; A Paracchi
Journal:  J Endocrinol Invest       Date:  1979 Jan-Mar       Impact factor: 4.256

7.  Involvement of the adrenal glands in the hypotensive response to bromocriptine in spontaneously hypertensive rats.

Authors:  T C Hamilton
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

8.  Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Authors:  E Flückiger; U Briner; B Clark; A Closse; A Enz; P Gull; A Hofmann; R Markstein; L Tolcsvai; H R Wagner
Journal:  Experientia       Date:  1988-05-15

9.  Dopamine agonists and cobalt-induced epilepsy in the rat.

Authors:  I B Farjo; J K McQueen
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

10.  Plasma bromocriptine levels, clinical and growth hormone responses in Parkinsonism.

Authors:  P Price; A Debono; J D Parkes; C D Marsden; J Rosenthaler
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.